Neuroscience Focus Areas:
Our other therapy areas

    • {%itemName%}
        {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%itemKeyName%} {%itemBadges%} {%arrowSpan%}
      {%selfProduct%}
    • {%itemName%}
      • {%countries%}
    • {%allMenuItem%}
      • {%languages%}

      • This website is for UK Healthcare Professionals only

      UK-BNO-230019. DOP: January 2023.

      Trust BOTOX® for your patients with post-stroke spasticity (PSS)

      UPPER LIMB & LOWER LIMB:

      BOTOX® has proven evidence and experience in post stroke spasticity in both the upper & lower limb in a range of muscles5-7

      PROVEN EFFICACY: 

      For these patients, BOTOX® showed reduced muscle tone, reduced pain and greater functional goal achievement compared to baseline6-8 

      PROVEN TOLERABILITY: 

      BOTOX® has safety and tolerability experience from +30 years of use in a range of conditions1,5,9,10

       

      Early identification should affect course of intervention in PSS, which will be key for patients' outcomes.11

       

      PSS: post-stroke spasticity.

      BOTOX® (botulinum toxin type A) is indicated for the treatment of focal spasticity including:5

      • wrist and hand disability due to upper limb spasticity associated with stroke in adults
      • ankle and foot disability due to lower limb spasticity associated with stroke in adults

       

      References

      1. Allergan. Data on file. INT/0423/2016(1). 2018.
      2. Aurora S K, Winner P et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 2011;51(9):1358-1373
      3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain 2018;19(1):13
      4. Allergan. Data on file. 014
      5. BOTOX® Summary of Product Characteristics. Available at: www.medicines.org.uk. Accessed October 2022
      6. Brashear A, Gordon MF et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. NEJM 2002; 347:395-400
      7. Kaji R, Osako Y et al. Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial. J Neurol. 2010;257(8):1330-7
      8. Gordon MF, Brashear A et al. Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology. 2004 ;63(10):1971-3
      9. Allergan. Data on file. INT/0572/2016(2). 2019
      10. Naumann M, Albanese A et al. Safety and efficacy of botulinum toxin type A following long-term use. Eur J Neurol. 2006;13 Suppl 4:35-40
      11. Wissel J, Verrier M et al. Post-stroke spasticity: predictors of early development and considerations for therapeutic intervention. PM R. 2015;7(1):60-7

      Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use.

      BOTOX® PRESCRIBING INFORMATION

       

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores.

      Adverse events should also be reported to AbbVie on [email protected]

       

      Date of preparation: October 2022. UK-BTX-220205.